Cantor Fitzgerald keeps Elevance stock rating on Medicare concerns
Cantor Fitzgerald maintained an Overweight rating and $450 price target for Elevance Health (ELV) despite a decline in its 2027 Medicare Stars ratings. The firm expects pressure on the stock due to concerns around Medicare Advantage management. Elevance reaffirmed its 2026 earnings guidance, projecting at least $20.10 per diluted share. Analysts have mixed views, with Guggenheim raising its target to $455 and RBC lowering it to $424.
How this was made
The 30-second read
Why it matters
The downgrade in stars raises investor caution, but the stock's pre‑market surge indicates short‑term optimism.
Market read
ELV shares moved sharply on new Medicare Stars data; analysts' views may drive near‑term price action.
What to watch
Humana and UnitedHealth's relative performance and Medicaid exit strategy could offset ELV concerns.
Background
Cantor Fitzgerald's rating maintenance follows the release of 2027 Medicare Stars ratings, a key metric for health insurers.
Ticker impact
Cantor Fitzgerald maintained an Overweight rating on Elevance Health (ELV) after the release of 2027 Medicare Stars ratings showing a decline to 47%, raising concerns about its Medicare Advantage business.
potential downside as investors price in Medicare Advantage concerns
Stars rating is a fresh, material data point; analysts note pressure on the stock.
Market effects
Medicare Advantage sector may see heightened scrutiny on stars ratings.
U.S. health‑insurance market reacts to rating changes.
Limited to U.S. insurers; no broader global effect.
Counterpoint
The 15% pre‑market rally suggests the market may have already priced in the stars decline.
Key entities
- companyElevance Health
U.S. health insurer (ticker ELV) subject of the rating and stars update.
- analystCantor Fitzgerald
Research firm maintaining Overweight rating on ELV.
